GC
ACAD icon

Globeflex Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Globeflex Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,536
Closed -$201K – 389
2025
Q4 		$201K Buy
+7,536
New +$180K 0.03% 294
2025
Q2 		– Sell
-9,155
Closed -$152K – 420
2025
Q1 		$152K Hold
9,155
– – 0.01% 330
2024
Q4 		$168K Buy
+9,155
New +$148K 0.01% 330

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Globeflex Capital's ACAD Position: Q1 2026 in Review

Globeflex Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 7,536 shares — an estimated $201K sold.

Globeflex Capital first reported a position in ACAD in Q4 2024 and held it in 3 quarters. The position peaked at $201K in Q4 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Globeflex Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Globeflex Capital sold 7,536 Acadia Pharmaceuticals shares in Q1 2026, an estimated $201K.
  • Globeflex Capital first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Globeflex Capital's Acadia Pharmaceuticals position peaked at $201K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.